# A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

> **NCT07175493** · PHASE1,PHASE2 · RECRUITING · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 158 (estimated)

## Conditions studied

- Autoimmune Cytopenia
- Immune Thrombocytopenia (ITP)
- Autoimmune Hemolytic Anemia
- Evans Syndrome

## Interventions

- **BIOLOGICAL:** CM336 Injection

## Key facts

- **NCT ID:** NCT07175493
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2027-11-18
- **Final completion:** 2028-11-18
- **Target enrollment:** 158 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07175493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07175493, "A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07175493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*